Cardiff Oncology to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC

Rhea-AI Summary

Cardiff Oncology, a clinical-stage biotechnology company, announced that CEO Mark Erlander will present at the 2022 Virtual Growth Conference from March 28-30, 2022. The fireside chat is scheduled for March 28 at 2:30 PM ET. The conference will be hosted by Maxim Group LLC and streamed live on M-Vest. Additionally, Dr. Erlander will provide a pre-recorded overview of the company's clinical and corporate strategy. Cardiff Oncology focuses on developing therapies targeting cancers using its lead asset, onvansertib, a PLK1 inhibitor. For more information, visit their website.

SAN DIEGO, March 22, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that CEO Mark Erlander, Ph.D., has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28^th – 30^th from 9:00 AM - 5:00 PM EDT.

Details on the presentation can be found below.

Presentation Format:	Fireside Chat
Presentation Date:	March 28, 2022
Presentation Time:	2:30 PM ET

In addition to the fireside chat, Dr. Erlander will also provide a pre-recorded overview of Cardiff Oncology's clinical and corporate strategy. The pre-recorded presentation will be available throughout the duration of the conference, which will be streamed live on M-Vest. To attend, sign up to become an M-Vest member here.

A replay of the fireside chat will be available by visiting the "Events" section on the investor page of the Cardiff Oncology website after the conference's conclusion.

About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers. Our lead asset is onvansertib, a PLK1 inhibitor we are evaluating in combination with standard-of-care (SOC) therapeutics in clinical programs targeting indications such as KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer. These programs and our broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SOC. For more information, please visit https://www.cardiffoncology.com

Cardiff Oncology Contact:
Vicki Kelemen
Chief Operating Officer
858-952-7652
vkelemen@cardiffoncology.com 

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com 

Media Contact:
Amy Jobe, Ph.D.
LifeSci Communications
315-879-8192
ajobe@lifescicomms.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiff-oncology-to-participate-in-the-2022-virtual-growth-conference-presented-by-maxim-group-llc-301507797.html

SOURCE Cardiff Oncology, Inc.

FAQ

When is Cardiff Oncology's presentation at the 2022 Virtual Growth Conference?

Cardiff Oncology's presentation is scheduled for March 28, 2022, at 2:30 PM ET.

Who will represent Cardiff Oncology at the conference?

CEO Mark Erlander will represent Cardiff Oncology at the conference.

What is the focus of Cardiff Oncology's research?

Cardiff Oncology focuses on developing novel therapies targeting cancers using PLK1 inhibition, particularly with their lead asset, onvansertib.

How can one attend the 2022 Virtual Growth Conference?

To attend the conference, sign up to become an M-Vest member.

Where can I find the replay of Cardiff Oncology's fireside chat?

The replay will be available in the 'Events' section on Cardiff Oncology's investor page after the conference.